Patient-reported Outcomes-driven Supportive Care Navigation Among Hispanic/Latinx Cancer Patients
26. august 2026 opdateret af: Alexandre Chan, University of California, Irvine
A Randomized Controlled, Type 1 Hybrid Effectiveness-implementation Trial Study to Compare the Effectiveness of a Patient-Reported Outcomes (PRO)-Driven Culturally Grounded Supportive Care Navigation in Reducing Healthcare Disparities Among Hispanic/Latinx Patients Receiving Anticancer Therapies
This is a randomized controlled, type 1 hybrid effectiveness-implementation trial to evaluate the effectiveness of a patient-reported outcomes (PRO)-driven culturally grounded supportive care navigation in reducing healthcare disparities among Hispanic/Latinx patients receiving anticancer therapies.
The objectives of this study are: (1) to compare the effectiveness of an ePRO-driven culturally grounded supportive care navigation versus usual care (control) in Hispanic/Latinx patients undergoing anticancer treatment; and (2) to elicit perspectives from Hispanic/Latinx patients, healthcare providers, and community partners on how an ePRO-driven culturally grounded supportive care navigation can address health disparities.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
72
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Fan-Ying Chan, MS
- Telefonnummer: 949-738-7135
- E-mail: fanyinc@uci.edu
Undersøgelse Kontakt Backup
- Navn: Matthew Heshmatipour, MPH
- Telefonnummer: 9494624610
- E-mail: mheshmat@hs.uci.edu
Studiesteder
-
-
California
-
Irvine, California, Forenede Stater, 92617
- Chao Family Comprehensive Cancer Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- At least 18 years old
- Hispanic/LatinX origin
- Newly diagnosed cancer patients
- Receiving anticancer treatment (may include combinations of intravenous or oral chemotherapy, targeted therapies, and/or immunotherapies)
Exclusion Criteria:
- Being physically and/or mentally incapable of providing written consent
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Ingen indgriben: Sædvanlig pleje
|
|
|
Eksperimentel: Patient-Reported Outcomes (PRO)-driven supportive care navigation
|
Patients within the intervention arm will receive ePRO-driven supportive care navigation consisting of: (1) routine distress screening and care needs assessment; (2) machine learning-based acute care utilization risk prediction; (3) culturally grounded supportive care navigation; and (4) community follow-up.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Emergency department visits, hospitalizations, and urgent care visits
Tidsramme: baseline and 3 months post-baseline
|
Detailed information regarding emergency department visits, hospitalization, and urgent care visits from the first 3 months of anticancer treatment (after joining the study) will be obtained using electronic medical records, and the UCI Health Data Warehouse.
|
baseline and 3 months post-baseline
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Symptom severity
Tidsramme: baseline and 3 months post-baseline
|
Symptom severity will be assessed by the Edmonton Symptom Assessment System (ESAS), an 11-point Likert scale (0-10) that measures symptom intensity.
A change of at least one point is considered clinically meaningful, with higher scores indicating greater symptom burden.
|
baseline and 3 months post-baseline
|
|
Health-related quality of life
Tidsramme: baseline and 3 months post-baseline
|
Quality of life will be measured Patient-Reported Outcomes Measurement Information System Global Health (PROMIS Global Health), a 10-item Likert scale (questions 1-8 and 10 on a 5-point scale and question 9 on an 11-point scale) instrument yielding two scores, physical health and mental health, where higher scores indicate better health.
|
baseline and 3 months post-baseline
|
|
Health literacy
Tidsramme: baseline and 3 months post-baseline
|
Health literacy will be assessed using the Brief Health Literacy Screening (BHLS) tool, with each item rated on a 5-point scale from 1 to 5, yielding a total score ranging from 3 to 15.
Higher scores indicate better health literacy.
|
baseline and 3 months post-baseline
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
C-Reactive Protein (CRP) Level
Tidsramme: baseline and 3 months post-baseline
|
Dried blood spot (DBS) sampling will be used to collect and analyze CRP level (mg/L)
|
baseline and 3 months post-baseline
|
|
Interleukin-1 Receptor Antagonist (IL-1RA) Level
Tidsramme: Baseline and 3 months post-baseline
|
Dried blood spot (DBS) sampling will be used to collect and analyze IL-1RA level (pg/mL)
|
Baseline and 3 months post-baseline
|
|
Interleukin-6 (IL-6) Level
Tidsramme: Baseline and 3 months post-baseline
|
Dried blood spot (DBS) sampling will be used to collect and analyze IL-6 level (pg/mL)
|
Baseline and 3 months post-baseline
|
|
Tumor Necrosis Factor-alpha (TNF-α) Level
Tidsramme: Baseline and 3 months post-baseline
|
Dried blood spot (DBS) sampling will be used to collect and analyze TNF-α level (pg/mL)
|
Baseline and 3 months post-baseline
|
|
TNF Receptor Type II (TNF-RII) Level
Tidsramme: Baseline and 3 months post-baseline
|
Dried blood spot (DBS) sampling will be used to collect and analyze TNF-RII level (pg/mL)
|
Baseline and 3 months post-baseline
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Alexandre Chan, PharmD, PhD, MPH, University of California, Irvine
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004 Feb 15;22(4):714-24. doi: 10.1200/JCO.2004.06.078.
- Kotronoulas G, Kearney N, Maguire R, Harrow A, Di Domenico D, Croy S, MacGillivray S. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014 May 10;32(14):1480-501. doi: 10.1200/JCO.2013.53.5948. Epub 2014 Apr 7.
- Alvidrez J, Castille D, Laude-Sharp M, Rosario A, Tabor D. The National Institute on Minority Health and Health Disparities Research Framework. Am J Public Health. 2019 Jan;109(S1):S16-S20. doi: 10.2105/AJPH.2018.304883.
- Cooper LA, Roter DL, Johnson RL, Ford DE, Steinwachs DM, Powe NR. Patient-centered communication, ratings of care, and concordance of patient and physician race. Ann Intern Med. 2003 Dec 2;139(11):907-15. doi: 10.7326/0003-4819-139-11-200312020-00009.
- Wagner LI, Schink J, Bass M, Patel S, Diaz MV, Rothrock N, Pearman T, Gershon R, Penedo FJ, Rosen S, Cella D. Bringing PROMIS to practice: brief and precise symptom screening in ambulatory cancer care. Cancer. 2015 Mar 15;121(6):927-34. doi: 10.1002/cncr.29104. Epub 2014 Nov 6.
- Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014 Sep 29;106(9):dju244. doi: 10.1093/jnci/dju244. Print 2014 Sep.
- Basch E, Barbera L, Kerrigan CL, Velikova G. Implementation of Patient-Reported Outcomes in Routine Medical Care. Am Soc Clin Oncol Educ Book. 2018 May 23;38:122-134. doi: 10.1200/EDBK_200383.
- Cheung YT, Chan A, Charalambous A, Darling HS, Eng L, Grech L, van den Hurk CJG, Kirk D, Mitchell SA, Poprawski D, Rammant E, Ramsey I, Fitch MI, Chan RJ. The use of patient-reported outcomes in routine cancer care: preliminary insights from a multinational scoping survey of oncology practitioners. Support Care Cancer. 2022 Feb;30(2):1427-1439. doi: 10.1007/s00520-021-06545-7. Epub 2021 Sep 15.
- Chan RJ, Milch VE, Crawford-Williams F, Agbejule OA, Joseph R, Johal J, Dick N, Wallen MP, Ratcliffe J, Agarwal A, Nekhlyudov L, Tieu M, Al-Momani M, Turnbull S, Sathiaraj R, Keefe D, Hart NH. Patient navigation across the cancer care continuum: An overview of systematic reviews and emerging literature. CA Cancer J Clin. 2023 Nov-Dec;73(6):565-589. doi: 10.3322/caac.21788. Epub 2023 Jun 26.
- Santos Salas A, Fuentes Contreras J, Armijo-Olivo S, Saltaji H, Watanabe S, Chambers T, Walter L, Cummings GG. Non-pharmacological cancer pain interventions in populations with social disparities: a systematic review and meta-analysis. Support Care Cancer. 2016 Feb;24(2):985-1000. doi: 10.1007/s00520-015-2998-9. Epub 2015 Nov 10.
- Duma N, Velazquez AI, Franco I, Kiel L, Levit LA, Schenkel C, Kirkwood K, Green S, Rodriguez G. Donde Estan? Latinx/Hispanic Representation in the Oncology Workforce: Present and Future. JCO Oncol Pract. 2022 May;18(5):388-395. doi: 10.1200/OP.22.00153.
- Seible DM, Kundu S, Azuara A, Cherry DR, Arias S, Nalawade VV, Cruz J, Arreola R, Martinez ME, Nodora JN, Rahn DA, Murphy JD. The Influence of Patient-Provider Language Concordance in Cancer Care: Results of the Hispanic Outcomes by Language Approach (HOLA) Randomized Trial. Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):856-864. doi: 10.1016/j.ijrobp.2021.05.122. Epub 2021 May 29.
- Martinez KA, Snyder CF, Malin JL, Dy SM. Is race/ethnicity related to the presence or severity of pain in colorectal and lung cancer? J Pain Symptom Manage. 2014 Dec;48(6):1050-9. doi: 10.1016/j.jpainsymman.2014.02.005. Epub 2014 Apr 18.
- Reyes-Gibby CC, Anderson KO, Shete S, Bruera E, Yennurajalingam S. Early referral to supportive care specialists for symptom burden in lung cancer patients: a comparison of non-Hispanic whites, Hispanics, and non-Hispanic blacks. Cancer. 2012 Feb 1;118(3):856-63. doi: 10.1002/cncr.26312. Epub 2011 Jul 12.
- Duran DG, Perez-Stable EJ. Novel Approaches to Advance Minority Health and Health Disparities Research. Am J Public Health. 2019 Jan;109(S1):S8-S10. doi: 10.2105/AJPH.2018.304931. No abstract available.
- John DA, Kawachi I, Lathan CS, Ayanian JZ. Disparities in perceived unmet need for supportive services among patients with lung cancer in the Cancer Care Outcomes Research and Surveillance Consortium. Cancer. 2014 Oct 15;120(20):3178-91. doi: 10.1002/cncr.28801. Epub 2014 Jul 1.
- Chan A, Ng DQ, Arcos D, Heshmatipour M, Lee BJ, Chen A, Duong L, Van L, Nguyen T, Green V, Hoang D. Electronic Patient-Reported Outcome-Driven Symptom Management by Oncology Pharmacists in a Majority-Minority Population: An Implementation Study. JCO Oncol Pract. 2024 Dec;20(12):1744-1754. doi: 10.1200/OP.24.00050. Epub 2024 Jul 15.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
1. november 2026
Primær færdiggørelse (Anslået)
31. december 2027
Studieafslutning (Anslået)
31. december 2028
Datoer for studieregistrering
Først indsendt
22. august 2026
Først indsendt, der opfyldte QC-kriterier
22. august 2026
Først opslået (Faktiske)
26. august 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
31. august 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
26. august 2026
Sidst verificeret
1. august 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer
- Sundhedstjenester Administration
- Sundhedsvæsenets kvalitet, adgang og evaluering
- Undersøgelsesteknikker
- Epidemiologiske metoder
- Dataindsamling
- Evalueringsmekanismer til sundhedsvæsenet
- Sundhedskvalitet
- Folkesundhed
- Miljø og folkesundhed
- Sundhedsøkonomi og organisationer
- Resultatvurdering, sundhedsvæsen
- Resultat og procesvurdering, sundhedsvæsen
- Undersøgelser og spørgeskemaer
- Sundhedsplanlægning
- Undersøgelser af sundhedsvæsenet
- Sundhedstjenester forskning
- Vurdering af patientens resultat
- Patient rapporterede resultatmålinger
Andre undersøgelses-id-numre
- 25-43
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .